echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The Production Process of 3-[(2S,5S)-5-[(3R,5R)-3-hydroxy-6-iodo-5-methylhept-6-enyl]-4-methylideneoxolan-2-yl]propyl 2,2-dimethylpropanoate

    The Production Process of 3-[(2S,5S)-5-[(3R,5R)-3-hydroxy-6-iodo-5-methylhept-6-enyl]-4-methylideneoxolan-2-yl]propyl 2,2-dimethylpropanoate

    • Last Update: 2023-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The production process of 3-[(2S,5S)-5-[(3R,5R)-3-hydroxy-6-iodo-5-methylhept-6-enyl]-4-methylideneoxolan-2-yl]propyl 2,2-dimethylpropanoate, also known as the active ingredient in the medication Synulox, involves several steps and requires a high level of technical expertise and strict adherence to safety protocols.


    The production process begins with the synthesis of the compound 3-[(2S,5S)-5-[(3R,5R)-3-hydroxy-6-iodo-5-methylhept-6-enyl]-4-methylideneoxolan-2-yl]propyl 2,2-dimethylpropanoate.
    This involves a multi-step process that requires the use of specialized equipment and a team of skilled chemists.
    The synthesis process can take several days to complete, and requires constant monitoring and adjustment to ensure that the reaction conditions are optimal.


    Once the compound has been synthesized, it must be purified to remove any impurities that may have been introduced during the synthesis process.
    This involves the use of specialized equipment, such as high-performance liquid chromatography (HPLC) and gas chromatography (GC) machines, to separate the compound from any other substances that may be present.
    The purification process can take several days to complete, and requires strict adherence to safety protocols to prevent contamination of the compound.


    Once the compound has been purified, it is time to formulate it into a medication.
    This involves mixing the compound with other ingredients, such as excipients and preservatives, to create a stable and effective medication.
    The formulation process can take several weeks to complete, and requires strict adherence to quality control standards to ensure that the final product is safe and effective.


    Finally, the medication must be packaged and distributed to pharmacies and hospitals around the world.
    This involves the use of specialized packaging equipment and transportation methods to ensure that the medication remains stable and effective throughout the distribution process.


    In conclusion, the production process of 3-[(2S,5S)-5-[(3R,5R)-3-hydroxy-6-iodo-5-methylhept-6-enyl]-4-methylideneoxolan-2-yl]propyl 2,2-dimethylpropanoate, like Synulox, is a complex and technical process that requires a high level of expertise and strict adherence to safety protocols.
    The process involves several steps, from the synthesis of the compound to the formulation and distribution of the medication, and requires the use of specialized equipment and strict adherence to quality control standards


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.